Conclusion
NIVO + IPI and NIVO + Chemo in the Japanese subpopulation showed efficacy benefits compared with Chemo and had an acceptable safety profile, similar to reports from the global population. This Japanese sub-analysis showed that both NIVO + IPI and NIVO + Chemo treatments can become a new standard first-line treatment option for Japanese patients with advanced ESCC.